• Aucun résultat trouvé

Communiqué de l’Académie : Artemisia et Covid-19 – Académie nationale de médecine

N/A
N/A
Protected

Academic year: 2022

Partager "Communiqué de l’Académie : Artemisia et Covid-19 – Académie nationale de médecine"

Copied!
2
0
0

Texte intégral

(1)

Artemisia and Covid-19

Press release from the French National Academy of Medicine June 20, 2020

The announcement of the President of Madagascar on 20 April 2020 about the effectiveness of the "Covid-Organics" was widely covered by the media. It is a herbal tea or decoction based on Artemisia, developed by the Malagasy Institute for Applied Research (IMRA).

Distributed in 33 cl bottles or in dry herbal sachets under the brand name "CVO Tambavy", it contains 62% Artemisia annua and a mixture, in confidential proportions, of Malagasy medicinal plants used in the composition of traditional remedies as antiseptics and bronchial fluidizers.

However, the preventive and curative effectiveness of CVO Tambavy, proclaimed by government authorities and some infectious disease specialists from the capital, is not unanimous in the Malagasy medical community. The "Houses of Artemisia" network supports this initiative as well as several African countries that have already purchased, or received as donations, batches of “Covid-Organics”.

Since May 2020, IMRA has been preparing an injectable form for patients in respiratory distress. After having expressed significant reservations, the WHO Director-General ended up accepting to include Covid-Organics in the clinical trials of the “Solidarity Trial” program.

The National Academy of Medicine,

Noting:

- the lack of data on the molecules present in the dry matter of Artemisia annua produced in Madagascar,

- the absence of a preliminary study demonstrating antiviral activity of artemisinin in relation to SARS-CoV-2 in vitro,

- the lack of proof of concept and the empirical nature of the proposed therapeutic protocol, - the lack of controlled clinical studies of tolerance and efficacy;

Considering that the difficulty of conducting a clinical study to prove the efficacy of herbal medicine in the treatment of Covid-19 does not allow to bypass scientific rigor;

(2)

And recalling that the large-scale consumption of Artemisia herbal teas is likely to lead to the development of resistance to artemisinin-based antimalarials, essential for the treatment of uncomplicated Plasmodium falciparum malaria [1];

- Formally advises against the reckless use of Artemisia-based herbal teas or decoctions, in any form, for the treatment of Covid-19 until rigorously codified and scientifically supported therapeutic protocols have demonstrated their efficacy and safety in this indication.

[1] Danis M. Proposal for treatment of malaria with Artemisia leaves. Bull Acad Natl Med (2019) 203: 122-3. https://doi.org/10.1016/j.banm.2019.04.004

Références

Documents relatifs

With 4 to 5 million alcohol addicts, 13 million tobacco smokers and a million and a half of cannabis users, France is among the European countries one of the most exposed to

de s’assurer que les patients porteurs d’une affection psychiatrique chronique (schizophrénie, bipolarité...) et suspects de Covid-19 bénéficient d’une

to ensure that patients with a chronic psychiatric condition (schizophrenia, bipolarity, etc.) and suspected of Covid-19 benefit from effective monitoring at home and

- les patients cancéreux nécessitant des traitements doivent continuer à être pris en charge dans les services dédiés, y compris dans les établissements de

- cancer patients requiring treatment should continue to be cared for in dedicated services, including in health care facilities for Covid-19 patients;. - the practice

Les recommandations actuellement en vigueur pour les patients Covid-19 ayant une forme simple ou modérée de l’infection sont un confinement strict à domicile et

The current recommendations for Covid-19 patients with a simple or moderate form of the infection are strict confinement at home and the observation of barrier

Afin que la sortie du confinement se fasse dans les meilleures conditions de prise en charge des cas graves dans les établissements de santé, de limitation de la